|Home||Internet of Things||Aerospace||Apparel||Energy||Defense||Health Care||Logistics||Manufacturing||Retail|
U.S. Congressmen Seek to Specify a Track-and-Trace Technology for Drugs
At a House Committee on Energy and Commerce meeting, Reps Steve Buyer and Jim Matheson questioned the FDA and sought to gain support for HR 5839, which would require the agency to stipulate the technology to be used for a nationwide pedigree system.
May 01, 2008—U.S. House Representatives Steve Buyer (R-Ind.) and Jim Matheson (D-Utah) joined a hearing of the House Committee on Energy and Commerce today to glean support for a bill that would mandate the U.S. Food and Drug Administration (FDA) to generate a unified track-and-trace pedigree standard for pharmaceuticals as they traverse the supply chain. The sponsors hope their bill, the Safeguarding Pharmaceuticals Act of 2008 (HR 5839), will be included in the Food and Drug Administration Globalization Act—broader legislation the committee is currently reviewing and preparing to present to the House of Representatives.
HR 5839 reads similarly to the Food and Drug Administration Amendment Act (FDAAA) that passed in 2007, dictating that the FDA must specify a recommendation for drug identification by the end of March 2010. HR 5839 takes this a step further, however, requiring that the FDA issue a track-and-trace recommendation by the same date that spells out the technology to be used for a unified pedigree system.
Matheson, Heyrend says, "is concerned with the hodgepodge of efforts state by state for a pedigree system." The hope with this bill, she notes, is to mandate the FDA to create a single uniform national standard rather than allow each state to develop its own standard. "Obviously," she says, "he thinks this bill is the way to go with those key concerns." While the FDAAA requirement also puts the standardization in the hands of the FDA, it does not specifically require the track-and-trace technology to be standardized.
In addition, HR 5839 would enable the FDA to destroy any pharmaceuticals proven to be counterfeit or misbranded, or that were tampered with or diverted at some point in the supply chain. Such tampering could be identified, for instance, at the port of entry into the United States. At the committee hearing, Ilisa Bernstein, the FDA's senior advisor for regulator policy, told Buyer that in such cases, the FDA currently sends a letter of detention to the receiving party of the questionable pharmaceuticals, giving that party 20 days to respond.
If the FDA does not receive a response, that agency—or U.S. Customers and Border Protection (CBP) in the case of products seized as they enter the country—then either returns the drugs to the sender, or keeps them on a shelf for 90 days before destroying them. With the new measure, the FDA or CBP would be allowed to simply go to the site where the questionable pharmaceuticals are being held and destroy them immediately. Bernstein told Buyer that "streamlining the destruction authority would certainly be beneficial."
Login and post your comment!
Not a member?
Signup for an account now to access all of the features of RFIDJournal.com!
SEND IT YOUR WAY
RFID JOURNAL EVENTS
ASK THE EXPERTS
Simply enter a question for our experts.